jRCT2031260320招募中不适用
A Phase 1, Multicenter, Open-label, First-in-Human Trial of DS1025a in Participants with Advanced Solid Tumors
未提供0 个研究点目标入组 45 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Sign and date the main ICF, prior to the start of any trial-specific procedures.
- •Adults >=18 years of age at the time the ICF is signed (Please follow local regulatory requirements if the legal age of consent for trial participation is >18 years old).
- •Histologically documented, advanced, metastatic, or unresectable solid tumors.
- •Relapsed or refractory disease, following at least 1 line of therapy, not amenable to standard therapy.
- •Is willing to provide a newly obtained tumor tissue sample at screening, if not clinically contraindicated and at an acceptable risk as determined by the Investigator. If a fresh tumor biopsy is not clinically feasible or would pose unacceptable risk, an archival tumor tissue sample (obtained within 24 months of consent) must be submitted.
- •Has measurable disease based on local CT/MRI imaging as assessment by the Investigator using RECIST v1.1; radiographic tumor assessment must be performed within 28 days prior to initiation of trial intervention.
- •ECOG PS of 0 or 1 assessed no more than 28 days prior to initiation of trial intervention.
- •Has adequate organ and bone marrow function as assessed by local laboratory within 14 days prior to initiation of trial intervention as defined in the protocol.
- •A WOCBP is eligible to participate if the following conditions are met:
- •Participant is not pregnant as confirmed by highly sensitive pregnancy test
- •Participant does not plan to breastfeed during the Trial Intervention Period and for at least 8 months after last dose of trial intervention.
- •Participant agrees to adhere to a contraceptive method that is highly effective with low user dependency only and agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during the Treatment Period and for at least the time needed to eliminate the trial intervention after the last dose.
- •A male participant capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate the trial intervention:
- •Avoid donating sperm.
- •Adhere to approved contraception method as specified in the protocol.
排除标准
- •Prior treatment with an anti-CD25 therapy.
- •Treatment discontinuation history due to toxicity to a DXd-ADC agent and considered not able to tolerate DS1025a based on the discussion between the investigator and the Sponsor (for participants who have DXd-ADC treatment history).
- •Inadequate washout period before initiation of trial intervention as specified in the protocol.
- •Has spinal cord compression or clinically active central nervous system tumors, including metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.
- •Uncontrolled or significant cardiovascular disease as specified in the protocol.
- •Any of the following within the past 6 months prior to initiation of trial intervention: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event.
- •Participants with any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening.
- •Lung-specific intercurrent clinically significant illnesses as specified in the protocol.
- •Has clinically significant pulmonary compromise or requirement for supplemental oxygen.
- •History of other active malignancy within 3 years prior to initiation of trial intervention, with the exception of those with a negligible risk of metastasis or death (eg, 5-year OS rate >90%) and treated with expected curative outcome
- •Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE v 6.0, Grade <=1 or baseline.
- •History of hypersensitivity to any excipients in DS1025a or any known contraindication to treatment with, including hypersensitivity to, the trial intervention.
- •Has a known history of HLH.
- •Has a known active infection, or reactivation of latent following infections as specified in the protocol among participants who received treatment such as antivirals, antifungals, or IV antibiotics within 14 days prior to first dose of trial intervention.
- •Has active or uncontrolled HBV infection.
- •Has active or uncontrolled HCV infection.
- •Has active or uncontrolled HIV infection.
- •Has an active, known, or suspected autoimmune disease.
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10 mg daily prednisone equivalents) or any other form of immunosuppressive therapy within 14 days prior to the trial intervention.
研究者
相似试验
已完成
1 期
A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patients with CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia2023-510021-16-00Affimed GmbH60
招募中
不适用
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)metastatic castration-resistant prostate cancerjRCT20312602693
招募中
1 期
A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumorsadvanced refractory solid tumors2025-524192-24-00Samsung Bioepis Co. Ltd.40
招募中
1 期
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
招募中
1 期
A first-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers to assess safety, tolerability, and immunogenicity of PANHPVAX, a vaccine targeting human papilloma L2 antigen formulated with cyclic di-AMP2024-511493-67-00Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts45